Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053821597> ?p ?o ?g. }
- W2053821597 endingPage "S110" @default.
- W2053821597 startingPage "S101" @default.
- W2053821597 abstract "Although imatinib revolutionized the management of chronic myeloid leukemia (CML), recent data indicate a transformation in the treatment approach likely in the near future. For patients whose CML does not respond to standard-dose imatinib therapy, increasing the imatinib dose is a second-line option. However, high-dose imatinib is not an appropriate approach for patients experiencing drug toxicity, and there remain questions concerning the durability of responses achieved with this strategy. Alternative second-line options include the newer tyrosine kinase inhibitors (TKIs) such as dasatinib and nilotinib. A substantial amount of long-term data for these agents is available. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacological profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutational status. The superiority of second-generation TKIs over imatinib in newly diagnosed disease has been recognized as well. They induce high and rapid rates of cytogenetic and molecular response, with less progression to advanced forms of disease in comparison with imatinib. Several investigational agents specific for those patients with the T315I mutation remain under evaluation. The future of CML therapy may include early use of these potent agents to help more patients achieve molecular remission and potentially be a path to a CML cure." @default.
- W2053821597 created "2016-06-24" @default.
- W2053821597 creator A5015140142 @default.
- W2053821597 creator A5049385583 @default.
- W2053821597 creator A5059631346 @default.
- W2053821597 creator A5090435894 @default.
- W2053821597 date "2011-06-01" @default.
- W2053821597 modified "2023-10-15" @default.
- W2053821597 title "Outcome of Treatment of Chronic Myeloid Leukemia With Second-Generation Tyrosine Kinase Inhibitors After Imatinib Failure" @default.
- W2053821597 cites W120419820 @default.
- W2053821597 cites W1490418776 @default.
- W2053821597 cites W1606656369 @default.
- W2053821597 cites W1966239454 @default.
- W2053821597 cites W1967920366 @default.
- W2053821597 cites W1968892414 @default.
- W2053821597 cites W1976244025 @default.
- W2053821597 cites W1980571402 @default.
- W2053821597 cites W1983852790 @default.
- W2053821597 cites W1987702792 @default.
- W2053821597 cites W1999614615 @default.
- W2053821597 cites W2006917576 @default.
- W2053821597 cites W2014839361 @default.
- W2053821597 cites W2015713305 @default.
- W2053821597 cites W2025201739 @default.
- W2053821597 cites W2028959752 @default.
- W2053821597 cites W2031888170 @default.
- W2053821597 cites W2037602803 @default.
- W2053821597 cites W2038161969 @default.
- W2053821597 cites W2039021265 @default.
- W2053821597 cites W2044901721 @default.
- W2053821597 cites W2048809946 @default.
- W2053821597 cites W2053131280 @default.
- W2053821597 cites W2054251966 @default.
- W2053821597 cites W2059441519 @default.
- W2053821597 cites W2061860992 @default.
- W2053821597 cites W2063933529 @default.
- W2053821597 cites W2069023125 @default.
- W2053821597 cites W2070067474 @default.
- W2053821597 cites W2074740152 @default.
- W2053821597 cites W2075786831 @default.
- W2053821597 cites W2079517811 @default.
- W2053821597 cites W2080125373 @default.
- W2053821597 cites W2081638226 @default.
- W2053821597 cites W2083353096 @default.
- W2053821597 cites W2084199623 @default.
- W2053821597 cites W2090004346 @default.
- W2053821597 cites W2091005492 @default.
- W2053821597 cites W2091423586 @default.
- W2053821597 cites W2095911292 @default.
- W2053821597 cites W2097799776 @default.
- W2053821597 cites W2097946794 @default.
- W2053821597 cites W2101390452 @default.
- W2053821597 cites W2107015590 @default.
- W2053821597 cites W2107268345 @default.
- W2053821597 cites W2126579741 @default.
- W2053821597 cites W2131171876 @default.
- W2053821597 cites W2131174104 @default.
- W2053821597 cites W2134582745 @default.
- W2053821597 cites W2138807703 @default.
- W2053821597 cites W2140111850 @default.
- W2053821597 cites W2146658081 @default.
- W2053821597 cites W2151486690 @default.
- W2053821597 cites W2157436488 @default.
- W2053821597 cites W2160007211 @default.
- W2053821597 cites W2163773009 @default.
- W2053821597 cites W2166270808 @default.
- W2053821597 cites W2168633862 @default.
- W2053821597 cites W2172189430 @default.
- W2053821597 cites W2248211079 @default.
- W2053821597 cites W2248615526 @default.
- W2053821597 cites W2261840157 @default.
- W2053821597 cites W2263837564 @default.
- W2053821597 cites W2281554724 @default.
- W2053821597 cites W2281742031 @default.
- W2053821597 cites W2329648702 @default.
- W2053821597 cites W2467057658 @default.
- W2053821597 cites W2530270604 @default.
- W2053821597 cites W2553008434 @default.
- W2053821597 cites W2553125824 @default.
- W2053821597 cites W2557343987 @default.
- W2053821597 cites W2559594280 @default.
- W2053821597 cites W2560725846 @default.
- W2053821597 cites W2561489460 @default.
- W2053821597 cites W2564004309 @default.
- W2053821597 cites W2566861500 @default.
- W2053821597 cites W2570921152 @default.
- W2053821597 cites W2586659163 @default.
- W2053821597 cites W2588056253 @default.
- W2053821597 cites W2592892140 @default.
- W2053821597 cites W2979325951 @default.
- W2053821597 cites W4206293466 @default.
- W2053821597 cites W4241135227 @default.
- W2053821597 doi "https://doi.org/10.1016/j.clml.2011.02.009" @default.
- W2053821597 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4428283" @default.
- W2053821597 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22035738" @default.
- W2053821597 hasPublicationYear "2011" @default.
- W2053821597 type Work @default.
- W2053821597 sameAs 2053821597 @default.